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We synthesized on cellulose membranes 4942 ten-amino-acid peptides which included all of the sequences predicted for the severe
acute respiratory syndrome (SARS) corona virus. We probed these membranes with four pairs of acute and convalescent sera from
recovered SARS cases. We correlated positively reacting peptides with the in vitro SARS-CoV neutralizing activity of the samples. We
found that convalescent sera with high neutralizing activity recognized exclusively only a limited number of peptides on the membranes.
This suggests that antibodies against the epitopes represented by these peptides could be responsible for much of the SARS-CoV
neutralizing activity. The findings have implications for monitoring humoral responses to SARS-CoV as well as for developing a successful
SARS vaccine.
D 2004 Elsevier Inc. All rights reserved.Keywords: Immune response; SARS vaccine; Peptide membranesIntroduction
A newly identified virus named SARS-CoV has been
established as the etiological agent of severe acute respi-
ratory syndrome (SARS). A total of 8422 probable cases
of this highly infectious disease had been reported to
WHO by August 2003 including 916 deaths (http://
www.who.int/csr/sars/en/). The viral genome has been
sequenced (Marra et al., 2003; Rota et al., 2003). It
consists of 29751 nucleotides which contain 15 identifi-
able open reading frames (AY274119).
Peptides incorporating all of the sequences predicted in
the open reading frames of the SARS-CoV genome were
prepared on derivatized cellulose membranes using a robotic
peptide synthesizer (Autospot ASP 222, Intavis Bioanalyt-
ical Instruments, Lagenfeld, Germany). The peptides were
10 amino acids long and overlapped by eight residues. Each
peptide on a membrane was therefore shifted from the one0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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The arrangement of the 4942 peptides on sets of four
membranes covering the 15 open reading frames (Orfs) is
illustrated in Fig. 1.
Membranes were probed with pairs of acute and conva-
lescent sera from four cases who recovered from a SARS
infection. As controls, serum from one case that failed to
survive, and one from a healthy, nonexposed volunteer was
utilized. Samples were diluted 100-fold in buffer and then
applied to a membrane for 1 h at 37 jC. The membranes
were developed with horseradish peroxidase-conjugated
goat antibodies against human IgG, IgM, or IgA. Positive
spots were then identified following treatment with ECL
chemiluminescence reagents.
Sera were tested for the presence of antibodies against
SARS-CoV in a standard virus neutralizing test. Serial 2-
fold dilutions of each serum from 1/8 to 1/1024 were
incubated with 100 plaque-forming units of SARS-CoV
(Tor-2 isolate, Marra et al., 2003) for 2 h and then added
to monolayers of Vero E6 cells. The cultures were
examined after 72 h for the presence of characteristic
cytopathic effects. The dilution before the one at which
cytopathic effects were first noted was recorded as the
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Table 1
Neutralization titers of sera from recovered SARS cases plus a deceased
case and a nonexposed control
Recovered cases Acute Convalescent
Case 1 (F, 50) < 1/8 1/512
Case 2, (F, 45) < 1/8 1/32
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virus activity, were retested following heat treatment at
56 jC for 30 min. This process confirmed the presence
of neutralizing antibodies and eliminated the possibility
of nonspecific, heat-sensitive factors contributing to the
neutralizing activity.
Case 3, (M, 49) 1/8 1/64
Case 4, (F, 65) < 1/8 1/128
Deceased case (F, 77) < 1/8
Control case (M, 76) < 1/8
Age and sex of the cases are shown in brackets.Results and discussion
The results of neutralization assays for the various sera
are shown in Table 1, along with the age and sex of the
respective patients. Acute sera were collected on presenta-
tion, and convalescent sera collected 1 month later in case 1,
and at least 2 weeks later in cases 2, 3, and 4. The acute
serum of case 3 had a neutralizing antibody titer of 1/8,
which indicates the beginning of an immune response.
Other acute sera as well as the acute serum of the deceased
case taken 7 days after illness onset, and the healthy control,
had no detectable neutralizing activity.
These data indicate that the four recovered cases devel-
oped antibodies with viral neutralizing potency between the
time of acute and convalescent serum sampling. Therefore,
those peptides strongly recognized on membranes probed
with convalescent sera, but not with acute or control sera,
should be the most immunodominant and may include
SARS-CoV epitopes that are vulnerable to neutralization
by antibody. This analysis is limited to linear epitopes since
peptides on the membranes do not replicate conformational
epitopes or those that develop from posttranslational mod-
ifications such as glycosylation.
Three examples of membranes reacted with acute and
convalescent sera and developed with anti-IgA antibodies
are shown in Fig. 1. Fig. 1b compares the second panel of
membrane 1 probed with serum from the unexposed control,
the deceased case, convalescent serum from case 1, and acute
and convalescent serum from case 2. The panel has a total of
408 peptides encoded from the Orf 1a open reading frame
(see Fig. 1a). No spots were strongly immunostained except
for a single triad in the two convalescent sera. The peptides
in the triad have the following sequences: SDDYIKLNGP,
DYIKLNGPLT, and IKLNGPVG. The sequence IKLNGP is
common to all three. Fig. 1c compares the third panel of
membrane 2 probed with the acute and convalescent serumFig. 1. (a) Outline of the overlapping peptide set covering membranes M1, M2, M3
P3, and P4. Numbers in the boxes designate the location of each open reading fra
totals in brackets. This membrane was spotted with dye instead of amino acids. In
being shifted by two amino acids. Characterization of the immune response agains
role in the resolution of infection. However, epitopes recognized by multiple conv
(b–d) Examples of membrane panels probed with various serum samples and dev
control serum, acute as well as convalescent serum from case 2, convalescent seru
recognized only in the serum of the two convalescent cases. The peptide sequence
P3M2 probed with acute and chronic serum from case 2 and serum from the dec
recognized only by the convalescent serum. The peptide sequences from S-prot
probed with acute and convalescent serum from case 2 and convalescent serum fro
The peptide sequences from N-protein are QLPQGTTLPK, PQGTTLPKGF, andof case 2, and the deceased case. The panel has 408 peptides
encoded from the S-protein open reading frame. One triad of
spots was immunopositive, in the convalescent, but not the
acute serum. The triad has the following sequences:
FQPFQQFGRD, PFQQFGRDVS, and QQFGRDVSDF.
The common sequence is QQFGRD. Fig. 1d compares the
fourth panel of membrane 3 probed with acute and conva-
lescent serum of case 2, and the convalescent serum of case
1. The bottom half of the membrane has peptides encoded for
the complete nucleocapsid (N) protein open reading frame.
One triad was immunopositive in the two convalescent sera
but was not positive in the corresponding acute serum of case
2. The triad has the following sequences: QLPQGTTLPK,
PQGTTLPKGF, and GTTLPKGFYA with the common
sequence being GTTLPK.
Shown in Table 2 are the 24 overlapping membrane
peptides that were recognized exclusively, or much more
strongly, in multiple pairs of convalescent compared with
the respective acute sera. None of these peptides was
recognized by the serum from the deceased case or the
healthy control. There were two overlapping sequences
from Orf 1a, one from Orf 1b, six from N-protein, eleven
from S-protein, two from M-protein, one from E protein
and one from Orf 10. The remaining open reading frames
were not reactive in more than one serum sample. In the
table, those peptides listed with a sequence of 14 amino
acids were identified as a combination of three adjacent
spots on the membranes, whereas those listed with 12
were identified as a combination of two adjacent spots.
Common sequences therefore include residues 5–10 of
the 14-amino-acid peptides and 3–10 of the 12-amino-
acid peptides., and M4. Panels on the membranes are designated from left to right P1, P2,
me. The note to the right of M4P1 shows the key to the Orfs with peptide
actual membranes, each spot is a 10-amino-acid peptide with adjacent spots
t these single case epitopes promises to provide important insights into their
alescent sera may be the most important targets of neutralizing antibodies.
eloped with peroxidase-labeled goat antihuman IgA; (b) M1P2 probed with
m from case 1, and serum from the deceased case. Notice the triad of spots
s from Orf 1a are SDDYIKLNGP, DYIKLNGPLT, and IKLNGPLTVG. (c)
eased case. Panel 3 has peptides from S-protein. Notice the triad of spots
ein are FQPFQQFGRD, PFQQFGRDVS, and QQFGRDVSDF. (d) P4M3
m case 1. Notice the triad of spots recognized in the two convalescent sera.
GTTLPKGFYA.
Table 2
Overlapping membrane peptides recognized in SARS convalescent sera by
antibodies to IgG, IgM, and IgA*
Orf1a
QVASDNIKDCVKCF (case 1 IgG; case 4 IgM) aa 665–678
SDDYIKLNGPLTVG (cases 1, 3, 4 IgA) aa 1065–1078
Orf1b NQDVNLHSSRLS (case 2 IgA, IgM; case 4 IgA) aa 4725–4736
Nucleocapsid (N)-protein
QLPQGTTLPKGFYA (cases 1, 2 IgG; cases 1, 3, 4 IgA) aa 161–174
PTVTLLPAADMDDF (case 1 IgG; cases 3, 4 IgM) aa 391–404
QPLPQRQKKQPT (case 3 IgG; case 1 IgG) aa 381–392
YKTFPPTEPKKD (cases 1, 3, 4 IgA) aa 361–372
GGSQASSRSSSR (cases 1, 2 IgG; case 2 IgM) aa 179–190
IRQGTDYKHWPQ (cases 1, 2 IgG; case 1 IgM) aa 293–304
Spike (S)-protein
SDTLYLTQDLFLPF (cases 1, 2 IgM) aa 49–62
IDKGIYQTSNFR (cases 1, 3 IgA) aa 295–306
CPFGEVFNATKF (cases 2, 4 IgA) aa 323–334
CTPPALNCYWPLND (case 1 IgG, IgM; case 2 IgA) aa 467–480
FQPFQQFGRDVSDF (cases 3, 4 IgA) aa 545–558
RDVSDFTDSVRD (case 4 IgG, IgM) aa 553–564
PIGAGICASYHT (case 2 IgG; cases 1, 2, 4 IgA; cases 1, 3, 4 IgM)
aa 651–662
VSLLRSTSQKSI (cases 2, 4 IgA; cases 2, 3 IgM) aa 663–674
AIPTNFSISITTEV (case 4 IgG; cases 1, 2, 4 IgA; cases 1, 3, 4 IgM)
aa 695–708
QYGSFCTQLNRA (case 3 IgG; case 1 IgM) aa 737–748
PFAMQMAYRFNG (cases 2, 3, IgM) aa 879–890
Membrane (M)-protein
KEITVATSRTLS (case 1 IgG; cases 1, 2, 3, 4 IgA; case 1 IgM)
aa 165–176
GTITVEELKQLL (cases 3, 4 IgG; case 2 IgA; cases 1, 2, 3 IgM) aa 5–16
E-protein
TVYVYSRVKNLNSSEG (cases 1, 2, 3, 4 IgG; cases 1, 2 IgA; case 2 IgM)
aa 55–70
Orf10
HVLEDPCKVQH (cases 1, 2 IgA) aa 28–39
Sequences with 14 amino acids represent three adjacent peptides with a
common sequence from residues 5 to 10. Sequences with 12 amino acids
represent two adjacent peptides with a common sequence from residues 3 to
10. The amino acid positions (aa) in SARS-CoV open reading frames are
taken from BLAST at NCBI: http://www.ncbi.nlm.nih.gov/blast/Blast.cgi.
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recognized only by convalescent serum from one of the four
cases. Among these single case examples were peptides from
Orf 3, Orf 4, Orf 9, Orf 13, and Orf 14, indicating that the
virus expresses these proteins and that antibodies against
certain of their epitopes are being produced. Characterization
of the immune response against these single case epitopes
promises to provide important insights into their role in the
resolution of infection. However, epitopes recognized by
multiple convalescent sera may be the most important for
developing antibodies that will protect against the virus.
Our knowledge of the functions of the SARS-CoV
proteins is mostly derived from analogies with those of
other well-characterized corona viruses. Over 21 kb of the
total genome is taken up by Orf 1a and Orf 1b, which are
presumed to encode for proteins such as proteases and
polymerases that are associated with virus replication
(Marra et al., 2003; Ruan et al., 2003). The genome is
sufficiently unique to be proposed as belonging to a separategroup designated as Group IV (Marra et al., 2003; Ruan et
al., 2003), but this view is not consensual and it has been
noted that SARS-CoV is most closely related to group 2
coronaviruses (Snijder et al., 2003). Nevertheless, the struc-
tural proteins S, M, N, and E have been clearly identified in
virus grown in infected cells (Marra et al., 2003; Ruan et al.,
2003). The spike, or S-protein, protrudes from the outer
surface and is a strong candidate for facilitating viral entry
into host cells.
Li et al. (2003) have reported that the SARS-CoV S-
protein efficiently binds to angiotensin converting enzyme 2
of SARS-CoV permissive Vero E6 cells, suggesting that this
binding is a key step in SARS-CoV infectivity. Interaction
between the S-protein of a corona virus and specific
mammalian receptors can determine species sensitivity.
For example, when the S-protein ectodomain of mouse
corona hepatitis virus was replaced with that of the feline
infectious peritonitis virus, the viral particles were no longer
infective for mouse cells, but became infective for feline
cells (Kuo et al., 2000). SARS-CoV has been reported to
infect domestic cats and ferrets (Martina et al., 2003) so
these relationships may have relevance to this broader
species susceptibility. A further example of interaction
between the S-protein and mammalian receptors involves
CD13 or aminopeptidase N. It is the main mammalian
receptor for the S-protein of many coronaviruses. Substitu-
tion on human cells of the human CD13 N-glycosylation
site with the porcine N-glycosylation site resulted in a
failure to bind human corona virus-229E (Wentworth and
Holmes, 2001).
Antibodies directed against the 11 epitopes of S-protein
identified in Table 2 are therefore potential candidates for
neutralizing activity. Antibodies against M-protein and E-
protein epitopes could also be important although they are
smaller and are believed to be less exposed. The protein
encoded by Orf 10 may be displayed on the viral surface
and an immune response to it may contribute to the
resolution of disease.
Antibodies against Orf 1a, Orf 1b, and N-Protein prob-
ably are unlikely to have contributed to the in vitro neutral-
ization results. N-protein is internal and is probably
inaccessible in the brief exposure time of the neutralization
test, and the products of Orf 1a and Orf 1b are not believed
to be structural proteins. Nevertheless, they may be very
important to in vivo protection.
Given the complexity of antibodies produced in each
convalescent serum, it would be difficult to predict what the
relative contribution of each to the overall neutralizing
activity might be, particularly when antibodies against
conformational or carbohydrate-dependent epitopes might
be present. Nevertheless, high titers of those consistently
represented in the various convalescent sera might be
sufficient to confer immunity.
Numerous strategies have been suggested for producing
a SARS vaccine (DeGroot, 2003). One possibility is to use a
combination of peptides, such as those listed in Table 2, as a
J.-P. Guo et al. / Virology 324 (2004) 251–256 255polyvalent antigen. Peptide-based vaccines have heretofore
had only limited success but this can be attributed to a lack
of knowledge as to which peptides to use. Such uncertainty
is reduced by analyzing the antibody pattern in sera from
cases that have successfully resolved the infection. Peptides
making up the antigen can be screened in advance for
homologies to mammalian proteins, reducing the possibility
of self-attack. They can also be easily modified to cope with
viral mutations that could escape traditional vaccines. Sig-
nificant mutations have already been identified in SARS-
CoV (Ruan et al., 2003; Martina et al., 2003), indicating the
necessity of developing adaptable vaccines.
Polypeptide vaccines should be safe, highly stable, and
easy to administer. Antibodies cloned against particularly
sensitive peptides could be used as therapeutic agents. The
type of analysis described here may have general utility in
designing peptide vaccines and therapeutic antibodies
against other infectious agents such as HIV.Methods
Cellulose-bound overlapping peptides (10 mers) derived
from all proteins encoded by the 15 Orfs of the SARS
genome were synthesized using an AutoSpot robot provided
by Intavis Bioanalytical Instruments. The software used for
designing the arrays was from DIGEN, Jerini Biotools
GmbH, Berlin, Germany. Membranes derivatized with a
polyethylene (PEG) linker and a free amino terminal, as
well as 9-fluorenylmethyloxycarbonyl (fmoc) amino acids
were obtained from Intavis Bioanalytical Instruments. The
fmoc amino acids (0.25 M) were dissolved in dimethylfor-
mamide (DMF, Sigma, Oakville, Ont. Canada) and then
activated with 1-hydroxybenzotriazole (HOBT, Sigma) and
N, N V-disopropylcarbodiimide (DIPC, Sigma) for at least 15
min. They were then delivered to the membrane in 60-nl
aliquots per spot by the robotic synthesizer. Fifteen minutes
after completion of each cycle, the membranes were re-
moved from the apparatus and treated with 2% acetic
anhydride in DMF to acetylate any free remaining amino
groups. They were then washed and further treated withFig. 2. (a) Vero E6 cells were imaged before infection and (b) 32 h after infection
damage in (b).20% piperidine in DMF to remove the fmoc protecting
group. This was followed by washing with DMF and
methanol, and finally by air drying. The membrane was
then precisely repositioned on the robotic apparatus to
initiate the next coupling cycle. After the final cycle, the
side chain protecting groups were removed by treatment
with a solution of the following composition: 5 ml of 50%
trifluoracetic acid; 5 ml dichloromethane (DCM); 300
Al triisopropyl silane (Sigma); and 200 Al water. Membranes
were then washed twice with DCM, twice with DMF, and
twice with methanol. After air drying, membranes were
stored in a sealed bag at 4 jC until used.
Membranes were rehydrated by treating first with meth-
anol, then 50% methanol followed by washing three times
in 50 mm Tris-buffered saline/0.2% Tween 20 (TBS-T).
They were then blocked with 5% skim milk in TBS-T
overnight at 4 jC. After washing three times with TBS-T,
the membranes were incubated at 37 jC for 1 h with 1/100
dilutions of serum samples of patients and controls. After
washing, membranes were treated with 1/5000 dilutions (0.2
Ag/ml) of goat antihuman IgA, IgG and IgM antibodies
conjugated to horseradish peroxidase (Sigma). After wash-
ing in TBS-T, membranes were developed with an ECL
chemiluminescence kit provided by Amersham Pharmacia
Biotech (Buckinghamshire, England). Four milliliters of the
two ECL Western blotting detection reagents were mixed
before being applied on the membranes. The membranes
were scanned using a Bio-Rad Fluorescent Imager (Hercu-
les, CA) and saved for later analysis. The membranes were
regenerated by incubation in 8 M urea/1% SDS overnight
followed by 60 min in 50% ethanol/10% acetic acid. After
this step, membranes were washed three times in methanol,
and after air drying stored at 4 jC in a sealed bag until reuse.
In initial development of the SARS-CoV serum neutral-
ization test, comparisons were made between the micro-
neutralization test and a 50% plaque reduction assay.
Testing of several sera consistently produced assay results
where the 50% plaque reduction titer was 2-fold greater than
in the microneutralization test. Following this validation, the
microneutralization test system was adopted for greater
convenience despite the 2-fold greater sensitivity of thewith SARS-CoV at a multiplicity of 1 pfu per cell. Notice the extensive cell
J.-P. Guo et al. / Virology 324 (2004) 251–256256plaque reduction assay. Typical results of this assay are
illustrated in Fig. 2.Acknowledgments
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